Compensation of 1.5 billion yuan!

On November 12, 2021, Osaka, Japan, Ono Pharmaceutical Co.
, Ltd.
announced that the company and Nobel laureate Dr.
Tasuku Honjo have reached a settlement agreement to resolve the lawsuit filed
.

Pharmaceutical Co.
, Ltd.
) announced that the company has reached a settlement agreement with Nobel Prize winner Dr.
Tasuku Honjo to resolve the lawsuit
.

Ono Pharmaceuticals will pay 5 billion yen to Dr.
Honjo, and Ono Pharmaceuticals will donate 23 billion yen to the "Ono Pharmaceuticals and Dr.
Honjo Honorary Research Fund" established by Kyoto University under voluntary and internal considerations
.

The future education and research environment as well as Kyoto University’s education and research support projects, and showcase new forms of industry-university cooperation in Japan

Ono Pharmaceuticals will pay 5 billion yen to Dr.

Dr.

In 1992, Honjo discovered programmed cell death protein 1 (PD-1), which is a key participant in tumor immunology

Image source:In an interview with Asian Scientist Magazine in 2016, Honjo said that his personal philosophy is to show "curiosity, courage and challenge" in his research pursuit
.

Two years later, Honjo won the Nobel Prize in Physiology and Medicine for discovering PD-1 and its importance for cancer immunotherapy

In an interview with Asian Scientist Magazine in 2016, Honjo said that his personal philosophy is to show "curiosity, courage and challenge" in his research pursuit .
Two years later, Honjo won the Nobel Prize in Physiology and Medicine for discovering PD-1 and its importance for cancer immunotherapy .
In an interview with Asian Scientist Magazine in 2016, Honjo said that his personal philosophy is to show "curiosity, courage and challenge" in his research pursuit

In 2018, Tasuku Honjo won the Nobel Prize in Physiology or Medicine

This disturbance began in the early 21st century, when Honjo wanted to apply for a patent for his PD-1 research results
.

But at that time, Japanese universities, including Kyoto University, "have no ability to manage or apply for patents, and cannot even pay for patent applications.

"Ono and I have not had any cooperation in scientific research, but they helped me apply for a patent," said Shuyou Ben at the time
.

Subsequently, many laboratories have developed drugs that target PD-1
.

Honjo and Ono Pharmaceuticals jointly hold some key patents.

Opdivo's sales in fiscal 2020 reached 98.
8 billion yen (approximately US$870 million), an increase of 13% year-on-year
.

Mainly because it was approved in February last year to treat patients with unresectable advanced/recurrent esophageal cancer, this is the first time Opdivo has been approved for the treatment of patients with advanced esophageal cancer, and it is also the first cancer immunotherapy approved in Japan for the treatment of patients with esophageal cancer

28 billion yen, about 1.
57 billion yuan
.
The settlement reached this time represents a complete settlement of the dispute between Ono Pharmaceuticals and Dr.
Tasuku Honjo.
It not only involves the 26.
2 billion yen litigation dividend related to the PD-1 patent third-party litigation filed on June 19, 2020, as well as ONO and The "PD-1 Gene Patent License Agreement" ("License Agreement") signed by Dr.
Honjo on October 23, 2006
.

28 billion yen, about 1.
57 billion yuan
.

O drug patent disputes are resolved, Ono Pharmaceuticals can go into battle lightly
.

O drug patent disputes are resolved, Ono Pharmaceuticals can go into battle lightly
.
O drug patent disputes are resolved, Ono Pharmaceuticals can go into battle lightly
.

Reference materials:

Reference materials:

https:// https://